news
Sonathera to use ultrasound for gene therapy delivery
Sonathera is developing a new method to precisely deliver gene therapies into cells using ultrasound. This approach could significantly impact muscular dystrophy and other genetic diseases by bypassing the usual viral vectors and targeting therapy to specific areas.
Sonathera is developing a new method to precisely deliver gene therapies into cells using ultrasound. This approach could significantly impact muscular dystrophy and other genetic diseases by bypassing the usual viral vectors and targeting therapy to specific areas.
The architecture take
Think of gene therapy's biggest problem: getting the goods exactly where they need to go without causing a global immune freak-out. Traditional viral vectors spray gene-editing material all over, which can have some gnarly side effects. Sonathera's playing a smarter game here, using ultrasound to gently poke holes in cell membranes in specific tissues, like a microscopic, guided missile. This means you could theoretically target, say, only muscle cells in a Duchenne patient, or specific neurons. It's a huge leap toward precision medicine that directly impacts the body's internal workings, reducing systemic impact and making these advanced therapies way more tolerable. The market implication here is a move away from 'spray and pray' gene delivery to highly localized, dialed-in interventions.